The global Active Pharmaceutical Ingredients (API) market is on track to reach $245 billion by 2028, fueled by a convergence of patent cliffs, expanding generic drug markets, and the rapid growth of biological medicines. According to the latest industry analysis, the market is expected to grow at a compound annual rate of 6.2% from 2024 through 2028.
Key drivers include the increasing prevalence of chronic diseases, the rise of biosimilars entering major markets after blockbuster patent expirations, and government initiatives across emerging economies to build domestic API manufacturing capabilities. India and China continue to dominate production volumes, though reshoring efforts in the US and EU are gaining momentum.
Contract Development and Manufacturing Organizations (CDMOs) are the biggest beneficiaries of this trend. Companies with GMP-certified facilities and proven regulatory track records are seeing order books fill up 12-18 months in advance. The bottleneck is no longer demand ??? it is qualified manufacturing capacity.
For sourcing professionals, this landscape underscores the importance of diversifying supplier networks, securing multi-year agreements for critical APIs, and investing in supply chain visibility tools. Early engagement with CDMO partners and robust quality auditing processes will be critical differentiators.